TY - THES A1 - Frydrychowicz, Alex T1 - Hochaufgelöste cine-Magnetresonanz-Bildgebung des Mäuseherzens zur Bestimmung rechtsventrikulärer Morphologie und funktioneller Parameter : Validierung der Methode und Etablierung an zwei Modellen der Herzinsuffizienz T1 - High-resolution cardiac cine-MR-Imaging of the murine right ventricle:Quantification of morphological and functional parameters and results from two models of induced heart failure N2 - Die Rolle des rechten Ventrikels in der Entwicklung der Herzinsuffizienz ist bis heute umstritten. Vor dem Hintergrund neuer transgener Mausmodelle war es Ziel dieser Studie, die MR-basierte Volumenquantifizierung für den rechten Ventrikel der Maus zu validieren und auf zwei Mausmodell mit Rechtsherzinsuffizienz anzuwenden. Gesunde Mäuse unterschiedlichen Alters wurden mittels MR-Bildgebung bei 7T untersucht. Zur Generierung der Herzinsuffizienz wurde eine Infarzierung durch Banding der LAD, zur Erzeugung einer isolierten Rechtsherzinsuffizienz eine Pulmonalarterienstenose operativ induziert. Die Schnittführung der MR-Aufnahmen lag orthogonal zum Ventrikelseptum, um Partialvolumen-Fehler zu minimieren. Die MR-Daten wurden von 2 unabhängigen Auswertern zur Bestimmung der Reproduzierbarkeit analysiert. Der Vergleich linksventrikulärer (LV) und rechtsventrikulärer (RV) Volumina zeigte eine enge Korrelation für die Schlagvolumina (SV) (r=0.97, p<0.0001). Die Bland-Altman-Analyse bestätigte diese enge Übereinstimmung (mittlere Differenz 0.4µl). Wiederholte Messung der RV Parameter zeigte ein hohes Maß an Reproduzierbarkeit (intraobserver- und interobserver-Variabilität jeweils <7%). Die MR-Messung 4 Wochen nach Pulmonalbanding ergab einen signifikanten Anstieg des RV enddiastolischen Volumens (+44%, p<0.005) und vor allem RV endsystolischen Volumens (+133%, p<0.0001). Die RV Ejektionsfraktion war signifikant reduziert (31.2±6.2 % vs. 57.0±2.3 %, p<0.001). Die LV Volumina sowie EF waren unverändert zum Normalkollektiv und bestätigten den Befund der isolierten Rechtsherzinsuffizienz. Neben LV Volumina erlaubt die 3D MR-Datenakquisition auch eine reproduzierbare Analyse des deutlich komplexeren rechten Ventrikels der Maus. Die Studie belegt eindrucksvoll des Potential von hochauflösender MR-Bildgebung zur Aufklärung von Pathomechanismen rechtsventrikulärer Erkrankungen. N2 - The predictive importance of the right ventricle (RV) in the failing heart is constantly discussed and MR-Imaging as a uniquely precise method is used to evaluate the underlying processes. The results from left ventricular (LV) murine cardiac MR-Imaging (MRI) led to the interest in assessing the RV by in vivo 7.05T cine-MRI and to demonstrate its potency on two models of heart failure. To demonstrate the feasibility of RV measurements RV volumes and parameters were compared to LV correlates and validated by inter- and intraobserver comparison. The method was then transferred to mice infarcted by LAD-banding as a model of heart failure and to a relatively unknown model of right heart failure by banding of the pulmonary artery. LAD-banding was performed as previously described by open-chest surgery. For pulmonary banding the pulmonary artery was dissected from other vascular structures and then banded against a prepared 25G needle for reproducibility of results1. All mice were given 4 weeks to recreate from the operation and to develop heart failure. MR studies were done by the known setup of our workgroup on a 7.05T experimental MR scanner (BRUKER Biospec, Germany) with a horizontal bore and a microscopy gradient insert. Adjacent planes were planned orthogonal to the interventricular septum as to depicture both RV and LV in a single measurement with highest possible precision and low geometric assumptions. Volume calculation was achieved by determining endsystolic and enddiastolic slices in every plane. Endo- and epicardial borders were then manually delineated for both left and right ventricle and added up for total ventricular volume (see figures 1-4). After comparison of LV and RV EDV, ESV, SV, CO and EF for validation of the method by one observer, a different observer repeatedly assessed RV volumes of each mouse for determination of inter- and intraobserver variability. After RV evaluation was thereby validated, the method was transferred onto the above models. Comparison of LV and RV in healthy mice showed close correlations (r=0.97, p<0.0001) between SV and CO as expected from human physiology. LV and RV EDV, ESV and EF differed as expected: RV EDV and ESV were significantly higher, RV EF lower than LV correlates (for all p<0.05). Repeated RV assessment for demonstration of inter- and intraobserver variability was done by a different observer: Calculations revealed low differences as shown in tables 1 and 2. Findings in the LAD-banding model were consistent with expectations from human pathophysiological changes with an obvious decrease of RV and LV SV, EF and CO. The relatively unknown banding of the pulmonary artery revealed unsignficantly altered LV parameters whereas RV EF was significantly lower. However, RV SV and CO were only slightly diminished which could be due to a slower progress of RV alterations than expected. We were able to demonstrate the feasibility of high-resolution MRI of the murine right ventricle with good results in direct RV and LV comparison. Inter- and Intraobserver validation of this method showed reasonably low differences which enabled us to successfully transfer this technique on two models of heart failure. These findings open new perspectives to further investigate RV changes both in healthy mice as well as in genetically or surgically engineered mice. Evaluation of the murine RV by MR-Imaging may therefore lead to a better understanding of the development of RV changes under pathophysiological circumstances. KW - Herzinsuffizienz KW - Kernspintomographie KW - Maus KW - RV KW - Model KW - Heart failure KW - murine KW - mri KW - mouse KW - pulmonal banding Y1 - 2004 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-10207 ER - TY - JOUR A1 - Haeussinger, Florian B. A1 - Heinzel, Sebastian A1 - Hahn, Tim A1 - Schecklmann, Martin A1 - Ehlis, Ann-Christine A1 - Fallgatter, Andreas J. T1 - Simulation of Near-Infrared Light Absorption Considering Individual Head and Prefrontal Cortex Anatomy: Implications for Optical Neuroimaging JF - PLoS ONE N2 - Functional near-infrared spectroscopy (fNIRS) is an established optical neuroimaging method for measuring functional hemodynamic responses to infer neural activation. However, the impact of individual anatomy on the sensitivity of fNIRS measuring hemodynamics within cortical gray matter is still unknown. By means of Monte Carlo simulations and structural MRI of 23 healthy subjects (mean age: (25.0 +/- 2.8) years), we characterized the individual distribution of tissue-specific NIR-light absorption underneath 24 prefrontal fNIRS channels. We, thereby, investigated the impact of scalp-cortex distance (SCD), frontal sinus volume as well as sulcal morphology on gray matter volumes (V(gray)) traversed by NIR-light, i.e. anatomy-dependent fNIRS sensitivity. The NIR-light absorption between optodes was distributed describing a rotational ellipsoid with a mean penetration depth of (23.6 +/- 0.7) mm considering the deepest 5% of light. Of the detected photon packages scalp and bone absorbed (96.4 +/- 9: 7)% and V(gray) absorbed (3.1 +/- 1.8)% of the energy. The mean V(gray) volume (1.1 +/- 0.4)cm(3) was negatively correlated (r = - .76) with the SCD and frontal sinus volume (r = - .57) and was reduced by 41.5% in subjects with relatively large compared to small frontal sinus. Head circumference was significantly positively correlated with the mean SCD (r = .46) and the traversed frontal sinus volume (r = .43). Sulcal morphology had no significant impact on V(gray). Our findings suggest to consider individual SCD and frontal sinus volume as anatomical factors impacting fNIRS sensitivity. Head circumference may represent a practical measure to partly control for these sources of error variance. KW - Beer-lambert law KW - Adult head KW - Human brain KW - Spectroscopy fnirs KW - Photon migration KW - Propagation KW - Scattering KW - Model KW - Tissues KW - Media Y1 - 2011 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-142311 VL - 6 IS - 10 ER - TY - JOUR A1 - Allignol, Arthur A1 - Schumacher, Martin A1 - Wanner, Christoph A1 - Drechsler, Christiane A1 - Beyersmann, Jan T1 - Understanding competing risks: a simulation point of view JF - BMC Medical Research Methodology N2 - Background: Competing risks methodology allows for an event-specific analysis of the single components of composite time-to-event endpoints. A key feature of competing risks is that there are as many hazards as there are competing risks. This is not always well accounted for in the applied literature. Methods: We advocate a simulation point of view for understanding competing risks. The hazards are envisaged as momentary event forces. They jointly determine the event time. Their relative magnitude determines the event type. 'Empirical simulations' using data from a recent study on cardiovascular events in diabetes patients illustrate subsequent interpretation. The method avoids concerns on identifiability and plausibility known from the latent failure time approach. Results: The 'empirical simulations' served as a proof of concept. Additionally manipulating baseline hazards and treatment effects illustrated both scenarios that require greater care for interpretation and how the simulation point of view aids the interpretation. The simulation algorithm applied to real data also provides for a general tool for study planning. Conclusions: There are as many hazards as there are competing risks. All of them should be analysed. This includes estimation of baseline hazards. Study planning must equally account for these aspects. KW - Cumulative incidence function KW - Clinical-trials KW - Sample-sizes KW - Regression KW - Subdistribution KW - Hazards KW - Model KW - Probabilities KW - Tests Y1 - 2011 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-142811 VL - 11 IS - 86 ER - TY - JOUR A1 - Ceteci, Fatih A1 - Xu, Jiajia A1 - Ceteci, Semra A1 - Zanucco, Emanuele A1 - Thakur, Chitra A1 - Rapp, Ulf R. T1 - Conditional Expression of Oncogenic C-RAF in Mouse Pulmonary Epithelial Cells Reveals Differential Tumorigenesis and Induction of Autophagy Leading to Tumor Regression JF - Neoplasia N2 - Here we describe a novel conditional mouse lung tumor model for investigation of the pathogenesis of human lung cancer. On the basis of the frequent involvement of the Ras-RAF-MEK-ERK signaling pathway in human non-small cell lung carcinoma (NSCLC), we have explored the target cell availability, reversibility, and cell type specificity of transformation by oncogenic C-RAF. Targeting expression to alveolar type II cells or to Clara cells, the two likely precursors of human NSCLC, revealed differential tumorigenicity between these cells. Whereas expression of oncogenic C-RAF in alveolar type II cells readily induced multifocal macroscopic lung tumors independent of the developmental state, few tumors with type II pneumocytes features and incomplete penetrance were found when targeted to Clara cells. Induced tumors did not progress and were strictly dependent on the initiating oncogene. Deinduction of mice resulted in tumor regression due to autophagy rather than apoptosis. Induction of autophagic cell death in regressing lung tumors suggests the use of autophagy enhancers as a treatment choice for patients with NSCLC. KW - Human lung-cancer KW - K-RAS KW - Induced senescence KW - Gene-expression KW - In-vivo KW - Kinase pathway KW - P53 KW - Activation KW - Model KW - Adenocarcinomas Y1 - 2011 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-134347 VL - 13 IS - 11 ER - TY - JOUR A1 - Groeber, Florian A1 - Schober, Lena A1 - Schmid, Freia F. A1 - Traube, Andrea A1 - Kolbus-Hernandez, Silvia A1 - Daton, Karolina A1 - Hoffmann, Sebastian A1 - Petersohn, Dirk A1 - Schaefer-Korting, Monika A1 - Walles, Heike A1 - Mewes, Karsten R. T1 - Catch-up validation study of an in vitro skin irritation test method based on an open source reconstructed epidermis (phase II) JF - Toxicology in Vitro N2 - To replace the Draize skin irritation assay (OECD guideline 404) several test methods based on reconstructed human epidermis (RHE) have been developed and were adopted in the OECD test guideline 439. However, all validated test methods in the guideline are linked to RHE provided by only three companies. Thus,the availability of these test models is dependent on the commercial interest of the producer. To overcome this limitation and thus to increase the accessibility of in vitro skin irritation testing, an open source reconstructed epidermis (OS-REp) was introduced. To demonstrate the capacity of the OS-REp in regulatory risk assessment, a catch-up-validation study was performed. The participating laboratories used in-house generated OS-REp to assess the set of 20 reference substances according to the performance standards amending the OECD test guideline 439. Testing was performed under blinded conditions. The within-laboratory reproducibility of 87% and the inter-laboratory reproducibility of 85% prove a high reliability of irritancy testing using the OS-REp protocol. In addition, the prediction capacity was with an accuracy of 80% comparable to previous published RHE based test protocols. Taken together the results indicate that the OS-REp test method can be used as a standalone alternative skin irritation test replacing the OECD test guideline 404. KW - Model KW - Chemicals KW - Assay KW - Episkin KW - Vivo KW - RHE KW - In vitro skin irritation testing KW - Open source reconstructed epidermis KW - Validation KW - Alternative test methods Y1 - 2016 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-187311 VL - 36 ER - TY - JOUR A1 - Hopp, Sarah A1 - Albert-Weissenberger, Christiane A1 - Mencl, Stine A1 - Bieber, Michael A1 - Schuhmann, Michael K. A1 - Stetter, Christian A1 - Nieswandt, Bernhard A1 - Schmidt, Peter M. A1 - Monoranu, Camelia-Maria A1 - Alafuzoff, Irina A1 - Marklund, Niklas A1 - Nolte, Marc W. A1 - Sirén, Anna-Leena A1 - Kleinschnitz, Christoph T1 - Targeting coagulation factor XII as a novel therapeutic option in brain trauma JF - Annals of Neurology N2 - Objective: Traumatic brain injury is a major global public health problem for which specific therapeutic interventions are lacking. There is, therefore, a pressing need to identify innovative pathomechanism-based effective therapies for this condition. Thrombus formation in the cerebral microcirculation has been proposed to contribute to secondary brain damage by causing pericontusional ischemia, but previous studies have failed to harness this finding for therapeutic use. The aim of this study was to obtain preclinical evidence supporting the hypothesis that targeting factor XII prevents thrombus formation and has a beneficial effect on outcome after traumatic brain injury. Methods: We investigated the impact of genetic deficiency of factor XII and acute inhibition of activated factor XII with a single bolus injection of recombinant human albumin-fused infestin-4 (rHA-Infestin-4) on trauma-induced microvascular thrombus formation and the subsequent outcome in 2 mouse models of traumatic brain injury. Results: Our study showed that both genetic deficiency of factor XII and an inhibition of activated factor XII in mice minimize trauma-induced microvascular thrombus formation and improve outcome, as reflected by better motor function, reduced brain lesion volume, and diminished neurodegeneration. Administration of human factor XII in factor XII-deficient mice fully restored injury-induced microvascular thrombus formation and brain damage. Interpretation: The robust protective effect of rHA-Infestin-4 points to a novel treatment option that can decrease ischemic injury after traumatic brain injury without increasing bleeding tendencies. KW - Molecular-weight heparin KW - Thrombus formation KW - Cerebral-ischemia KW - in-vivo KW - Intravascular coagulation KW - Hemodynamic depression KW - Head-injury KW - Rats KW - Model KW - Mice Y1 - 2016 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-188800 VL - 79 IS - 6 ER - TY - THES A1 - Bucher, Hannes T1 - Pre-clinical modeling of viral- and bacterial-induced exacerbations of chronic obstructive pulmonary disease T1 - Prä-klinische Modellierung von viral und bakteriell induzierten Exazerbationen von Chronisch Obstruktiver Lungenerkrankung N2 - Chronic Obstructive Pulmonary Disease (COPD) exacerbations are a considerable reason for increased morbidity and mortality in patients. Infections with influenza virus (H1N1), respiratory syncytial virus (RSV) or nontypeable Haemophilus influenzae (NTHi) are important triggers of exacerbations. To date, no treatments are available which can stop the progression of COPD. Novel approaches are urgently needed. Pre-clinical models of the disease are crucial for the development of novel therapeutic options. In order to establish pre-clinical models which mimic aspects of human COPD exacerbations, mice were exposed to cigarette smoke (CS) and additionally infected with H1N1, RSV and/or NTHi. Clinically relevant treatments such as the corticosteroids Fluticasone propionate and Dexamethasone, the phosphodiesterase-4 (PDE-4) inhibitor Roflumilast and the long-acting muscarinic receptor antagonist Tiotropium were tested in the established models. Furthermore, a novel treatment approach using antibodies (Abs) directed against IL-1α, IL-1β or IL-1R1 was examined in the established CS/H1N1 model. Levels of IFN-γ, IL-1β, IL-2, IL-6, KC, TNF-α, RANTES, IL-17, MCP-1, MIP 1α and MIP-1β were measured in lung homogenate. Numbers of total cells, neutrophils and macrophages were assessed in bronchoalveolar lavage (BAL) fluid. Hematoxylin- and eosin- (H&E-) stained lung slices were analyzed to detect pathological changes. Quantitative polymerase-chain-reaction (qPCR) was used to investigate gene expression of ICAM-1 and MUC5 A/C. The viral/bacterial load was investigated in lung homogenate or BAL fluid. In addition to the in vivo studies, the effects of the above mentioned treatments were investigated in vitro in H1N1, RSV or NTHi-infected (primary) human bronchial epithelial cells using submerged or air-liquid-interface (ALI) cell culture systems. Four pre-clinical models (CS/H1N1, CS/RSV, CS/NTHi, CS/H1N1/NTHi) were established depicting clinically relevant aspects of COPD exacerbations such as increased inflammatory cells and cytokines in the airways and impaired lung function. In the CS/H1N1 model, Tiotropium improved lung function and was superior in reducing inflammation in comparison to Fluticasone or Roflumilast. Moreover, Fluticasone increased the loss of body-weight, levels of IL-6, KC and TNF-α and worsened lung function. In CS/RSV-exposed mice Tiotropium but not Fluticasone or Roflumilast treatment reduced neutrophil numbers and IL-6 and TNF α levels in the lung. The viral load of H1N1 and RSV was significantly elevated in CS/virus-exposed mice and NCI-H292 cells after Fluticasone and Dexamethasone treatment. The results from these studies demonstrate that Tiotropium has anti-inflammatory effects on CS/virus-induced inflammation and might help to explain the observed reduction of exacerbation rates in Tiotropium-treated COPD patients. Furthermore, the findings from this work indicate that treatment with Fluticasone or Dexamethasone might not be beneficial to reduce inflammation in the airways of COPD patients and supports clinical studies that link treatment with corticosteroids to an increased risk for pneumonia. Testing of anti-IL-1α, anti-IL-1β or anti-IL-1R1 Abs in the CS/H1N1 model suggests that, in line with clinical data, antagonization of IL-1β is not sufficient to reduce pulmonary inflammation and indicates a predominant role of IL-1α in CS/virus-induced airway inflammation. In line with the in vivo findings, anti-IL-1α but not anti-IL-1β Abs reduced levels of TNF-α and IL-6 in H1N1-infected primary human bronchial epithelial ALI cell culture. Blocking the IL-1R1 provided significant inhibitory effects on inflammatory cells in vivo but was inferior compared to inhibiting both its soluble ligands IL-1α and IL-1β. Concomitant usage of Abs against IL-1α/IL-1β revealed strong effects and reduced total cells, neutrophils and macrophages. Additionally, levels of KC, IL-6, TNF-α, MCP-1, MIP-1α and MIP-1β were significantly reduced and ICAM-1 mRNA expression was attenuated. These results suggest that combined inhibition of IL-1α/IL-1β might be beneficial to reduce inflammation and exacerbations in COPD patients. Moreover, combined targeting of both IL-1α/IL-1β might be more efficient compared to inhibition of the IL-1R1. As in the CS/virus models, corticosteroid treatment failed to reduce inflammatory cells in the CS/NTHi and CS/H1N1/NTHi models, increased the loss of body-weight and the bacterial load. Furthermore, Roflumilast administration had no significant effects on cell counts or cytokines. However, it improved compliance in the CS/NTHi model. Treatment with Azithromycin reduced the bacterial load in the CS/NTHi model and reduced numbers of total cells, neutrophils, macrophages and levels of KC and TNF-α in the CS/H1N1/NTHi model. In conclusion, the established CS/H1N1, CS/RSV, CS/NTHi, CS/H1N1/NTHi models depict clinically relevant aspects of human COPD exacerbations in mice and provide the opportunity to investigate underlying disease mechanisms and to test novel therapies. N2 - Exazerbationen von Chronisch Obstruktiver Lungenerkrankung (COPD) sind ein bedeutender Grund für erhöhte Morbidität und Mortalität von Patienten. Infektionen mit Influenza Virus (H1N1), Respiratory Syncytial Virus (RSV) oder nontypeable Haemophilus influenzae (NTHi) gelten als wichtige Auslöser von Exazerbationen. Bis heute gibt es keine Therapien, welche die Progression von COPD verhindern können. Neue Therapieansätze werden daher dringend benötigt. Prä-klinische Modelle spielen bei der Entwicklung neuer Therapien eine entscheidende Rolle. Um Aspekte einer humanen COPD-Exazerbation abzubilden, wurden Mäuse Zigarettenrauch (CS) ausgesetzt und zusätzlich mit H1N1, RSV und/oder NTHi infiziert. Klinisch relevante Behandlungen, z.B. die Kortikosteroide Fluticasonpropionat und Dexamethason, der Phosphodiesterase 4 (PDE-4) Inhibitor Roflumilast und der muskarinische Rezeptorantagonist Tiotropium, wurden in den etablierten Modellen getestet. Zudem wurde ein neuer therapeutischer Ansatz untersucht bei dem IL-1α, IL-1β neutralisierende bzw. IL-1R1 blockierende Antikörper (Ak) zum Einsatz kamen. Die Mengen von IFN-γ, IL-1β, IL 2, IL-6, KC, TNF-α, RANTES, IL-17, MCP-1, MIP-1α und MIP-1β wurden im Lungenhomogenat gemessen. Die Gesamtzellzahl und die Anzahl von Neutrophilen und Makrophagen wurden in bronchoalveolärer Lavage (BAL) Flüssigkeit bestimmt. Hematoxylin- und Eosin- (H&E-) gefärbte Lungenschnitte wurden analysiert, um pathologische Veränderungen zu detektieren. Quantitative Polymerase-Kettenreaktion (qPCR) wurde genutzt, um die Genexpression von ICAM-1 und MUC5 A/C zu untersuchen. Die Virus /Bakterienlast wurde in BAL Flüssigkeit oder Lungenhomogenat gemessen. Darüber hinaus wurden die Effekte der oben genannten Behandlungen in vitro in H1N1, RSV oder NTHi infizierten (primären) humanen bronchialen Epithelzellen in „submerged“ oder „air-liquid-interface (ALI)“ Zellkultur-Systemen untersucht. Vier prä-klinische Modelle (CS/H1N1, CS/RSV, CS/NTHi, CS/H1N1/NTHi) wurden etabliert, die relevante Aspekte einer Exazerbation, wie beispielsweise den Einstrom inflammatorischer Zellen, erhöhte Zytokinlevel oder verminderte Lungenfunktion abbilden. Im CS/H1N1-Modell verbesserte Tiotropium die Lungenfunktion und zeigte stärker anti-entzündliche Effekte als Fluticason oder Roflumilast. Zudem verstärkte Fluticason den Gewichtsverlust, erhöhte die Level von IL-6 und TNF-α und verschlechterte die Lungenfunktion. Im CS/RSV-Modell reduzierte Tiotropium, aber nicht Fluticason oder Roflumilast die Zahl der Neutrophilen sowie IL-6 und TNF-α Mengen. Die Menge von H1N1 und RSV war in den CS/Virus-Modellen sowie in NCI-H292 Zellen nach Fluticason- oder Dexamethason-Behandlung signifikant erhöht. Die Ergebnisse dieser Studien demonstrieren anti-inflammatorische Effekte von Tiotropium auf CS/Virus-induzierte Entzündung und könnten helfen, reduzierte Exazerbationshäufigkeiten in mit Tiotropium behandelten Patienten zu erklären. Zudem könnten die Resultate dieser Arbeit darauf hindeuten, dass die Behandlung mit Kortikosteroiden nicht geeignet ist, um Entzündung in COPD-Patienten zu reduzieren, und könnten dabei helfen, das in klinischen Studien festgestellte erhöhte Risiko von Pneumonien bei Behandlung mit Kortikosteroiden zu erklären. Im Einklang mit klinischen Daten deutet die Testung von anti-IL-1α, anti-IL-1β oder anti IL-1R1 Ak im CS/H1N1-Modell darauf hin, dass die Neutralisation von IL-1β nicht ausreicht, um die Entzündung in der Lunge zu reduzieren, und impliziert eine prädominierende Rolle von IL-1α in CS/H1N1-induzierter Atemwegsentzündung. Konform mit den in vivo Ergebnissen, reduzierten anti-IL-1α, aber nicht anti-IL-1β Ak, TNF-α und IL-6 in H1N1-infizierter primärer humaner bronchialer epithelialer ALI-Zellkultur. Die Blockade von IL-1R1 zeigte in vivo signifikante inhibitorische Effekte auf inflammatorische Zellen, die verglichen mit der Neutralisation seiner löslichen Liganden IL-1α/IL-1β allerdings unterlegen waren. Die kombinierte Neutralisation von IL-1α/IL-1β war sehr effektiv und reduzierte die Gesamtzellzahl sowie die Zahl der Neutrophilen und Makrophagen in der Lunge. Zusätzlich wurden die Level von KC, IL-6, TNF-α, MCP-1, MIP-1α und MIP-1β signifikant reduziert. Diese Ergebnisse deuten darauf hin, dass kombinierte Inhibition von IL-1α/IL-1β geeignet sein könnte, um Entzündung und Exazerbationen in COPD-Patienten zu reduzieren. Zudem könnte IL-1α/IL-1β-Neutralisation effektiver sein als IL-1R1-Blockade. Wie in den CS/Virus-Modellen wurden inflammatorische Zellen durch Kortikosteroid-Behandlung im CS/NTHi- und CS/H1N1/NTHi-Modell nicht reduziert, verstärkten zudem den Gewichtsverlust und erhöhten die Bakterienmenge. Roflumilast zeigte keine Effekte auf Zellzahlen und Zytokine. Allerdings verbesserte die Behandlung damit die Compliance im CS/NTHi-Modell. Die Behandlung mit Azithromycin reduzierte die Bakterienmenge im CS/NTHi-Modell und reduzierte die Gesamtzellzahl und Anzahl von Neutrophilen und Makrophagen, sowie die Level von KC und TNF-α im CS/H1N1/NTHi-Modell. Zusammenfassend bilden die etablierten CS/H1N1-, CS/RSV-, CS/NTHi-, CS/H1N1/NTHi-Modelle klinisch relevante Aspekte von humanen COPD-Exazerbationen ab und ermöglichen die Erforschung von Krankheitsmechanismen und neuen Therapieansätze. KW - Obstruktive Ventilationsstörung KW - COPD KW - Exacerbation KW - Tiotropium KW - Influenza KW - NTHi KW - Preclinical KW - Model KW - Treatment KW - Exazerbation KW - Maus Y1 - 2018 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-144368 ER - TY - JOUR T1 - Search for top-squark pair production in final states with one lepton, jets, and missing transverse momentum using 36 fb\(^{-1}\) of root s=13 TeV \({pp}\) collision data with the ATLAS detector JF - Journal of High Energy Physics N2 - The results of a search for the direct pair production of top squarks, the supersymmetric partner of the top quark, in final states with one isolated electron or muon, several energetic jets, and missing transverse momentum are reported. The analysis also targets spin-0 mediator models, where the mediator decays into a pair of dark-matter particles and is produced in association with a pair of top quarks. The search uses data from proton-proton collisions delivered by the Large Hadron Collider in 2015 and 2016 at a centre-of-mass energy of root s = 13TeV and recorded by the ATLAS detector, corresponding to an integrated luminosity of 36 fb(-1). A wide range of signal scenarios with different mass-splittings between the top squark, the lightest neutralino and possible intermediate supersymmetric particles are considered, including cases where the W bosons or the top quarks produced in the decay chain are off-shell. No significant excess over the Standard Model prediction is observed. The null results are used to set exclusion limits at 95% confidence level in several supersymmetry benchmark models. For pair-produced top-squarks decaying into top quarks, top-squark masses up to 940 GeV are excluded. Stringent exclusion limits are also derived for all other considered top-squark decay scenarios. For the spin-0 mediator models, upper limits are set on the visible cross-section. KW - Hadron-Hadron scattering (experiments) KW - Dark-matter production KW - Symmetry-breaking KW - Plus plus KW - Model KW - Supersymmetry KW - Program KW - LHS KW - Mass KW - Extension KW - Physics Y1 - 2018 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-220733 VL - 108 IS - 6 ER - TY - THES A1 - Confalonieri, Davide T1 - Development and characterization of a bone marrow stem cell niche model T1 - Aufbau und Charakterisierung eines Knochenmark-Stammzellnischen-Modells N2 - Kritische Knochendefekte stellen heutzutage ein ungelöstes Problem in der klinischen Praxis dar, da die verfügbaren prothetischen Optionen oft die mechanische Anpassung an das Gewebe nicht gewährleisten oder zu wichtigen immunologischen und Implantat-bedingten Komplikationen führen. In diesem Kontext ermöglichen Tissue Engineering-Ansätze neue Strategien, um in vitro Zell-Material Interaktionen zu untersuchen und so die Implantatmaterialien zu optimieren. In dieser Arbeit habe ich Zell-Material Interaktionen eines neuen Kollagen-basierten Scaffolds untersucht, das langfristig als Trägerstruktur für eine zellbasierte Therapie für kritische Knochendefekte entwickelt werden soll. Im Rahmen der Dissertation konnte ich belegen, dass die Kollagen-basierten makroporöse Mikrocarrier für die Zellvermehrung humaner mesenchymaler Stammzellen (MSC) und deren osteogene Differenzierung unter GMP Bedingungen verwendet werden können. Außerdem habe ich die die Kokultur von hämatopoietischen Stammzellen des Knochenmarks und multiplen Myelomzellen funktionell charakterisiert. Ich konnte erstmals Kulturbedingungen etablieren, die die Langzeitkultur ohne die Verwendung von Zytokinen ermöglicht. Mittels dieser Kokultur konnte ich ein Knochenmarknischen-Modell etablieren und die Untersuchung der Expression von zentralen Signalkaskaden der Homöostase dieser Nische untersuchen. Ich konnte die Expression von zwei verschiedenen Isoformen von Osteopontin nachweisen, die in Tiermodellen nicht gefunden werden. Diese Isoformen des Osteopontins habe ich kloniert und die rekombinanten Isoformen exprimiert und ihre Rollen in der Homöostase der Knochenmarknische untersucht. Critical size bone defects represent nowadays an unresolved problem in the clinical practice, where the available prosthetic options often lack adequate mechanical matching to the host tissue or lead to important immunological and implant-related complications. In this context, Tissue Engineering approaches promise more effective strategies to study cell-material interactions in vitro and consequently optimize implant materials. In this work, I investigated the cell-scaffold interactions of a new collagen-based scaffold for a putative cell-based therapy for critical size defects to be developed. In the context of this thesis, I could demonstrate that the collagen-based macroporous microcarriers could be employed for the expansion and osteogenic differentiation of human mesenchymal stromal cells (MSCs) under GMP-compliant conditions. Moreover, I functionally characterized the co-culture of bone marrow hematopoietic stem cells and multiple myeloma cells. I was for the first time able to establish culture conditions allowing their long-term culture in absence of externally supplemented cytokines. Using this co-culture, I was able to establish a bone marrow niche model to investigate the expression of key signaling pathways involved in the niche´s homeostasis. I was able to demonstrate the expression of two different isoforms of Osteopontin, that could not previously be detected in animal models. Finally, I cloned these Osteopontin isoforms, expressed recombinant versions of the isoforms, and investigated their roles in the homeostasis of the bone marrow niche. N2 - Kritische Knochendefekte stellen heutzutage ein ungelöstes Problem in der klinischen Praxis dar, da die verfügbaren prothetischen Optionen oft die mechanische Anpassung an das Gewebe nicht gewährleisten oder zu wichtigen immunologischen und Implantat-bedingten Komplikationen führen. In diesem Kontext ermöglichen Tissue Engineering-Ansätze neue Strategien, um in vitro Zell-Material Interaktionen zu untersuchen und so die Implantatmaterialien zu optimieren. In dieser Arbeit habe ich Zell-Material Interaktionen eines neuen Kollagen-basierten Scaffolds untersucht, das langfristig als Trägerstruktur für eine zellbasierte Therapie für kritische Knochendefekte entwickelt werden soll. Im Rahmen der Dissertation konnte ich belegen, dass die Kollagen-basierten makroporöse Mikrocarrier für die Zellvermehrung humaner mesenchymaler Stammzellen (MSC) und deren osteogene Differenzierung unter GMP Bedingungen verwendet werden können. Außerdem habe ich die die Kokultur von hämatopoietischen Stammzellen des Knochenmarks und multiplen Myelomzellen funktionell charakterisiert. Ich konnte erstmals Kulturbedingungen etablieren, die die Langzeitkultur ohne die Verwendung von Zytokinen ermöglicht. Mittels dieser Kokultur konnte ich ein Knochenmarknischen-Modell etablieren und die Untersuchung der Expression von zentralen Signalkaskaden der Homöostase dieser Nische untersuchen. Ich konnte die Expression von zwei verschiedenen Isoformen von Osteopontin nachweisen, die in Tiermodellen nicht gefunden werden. Diese Isoformen des Osteopontins habe ich kloniert und die rekombinanten Isoformen exprimiert und ihre Rollen in der Homöostase der Knochenmarknische untersucht. KW - bone marrow niche KW - Bone KW - Marrow KW - Mesenchymal Stem Cell KW - Model KW - Hematopoietic Stem Cell Y1 - 2018 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-163128 ER - TY - JOUR T1 - Search for photonic signatures of gauge-mediated supersymmetry in 13 TeV \(pp\) collisions with the ATLAS detector JF - Physical Review D N2 - A search is presented for photonic signatures, motivated by generalized models of gauge-mediated supersymmetry breaking. This search makes use of proton-proton collision data at root s = 13 TeV corresponding to an integrated luminosity of 36.1 fb(-1) recorded by the ATLAS detector at the LHC, and it explores models dominated by both strong and electroweak production of supersymmetric partner states. Experimental signatures incorporating an isolated photon and significant missing transverse momentum are explored. These signatures include events with an additional photon or additional jet activity not associated with any specific underlying quark flavor. No significant excess of events is observed above the Standard Model prediction, and 95% confidence-level upper limits of between 0.083 and 0.32 fb are set on the visible cross section of contributions from physics beyond the Standard Model. These results are interpreted in terms of lower limits on the masses of gluinos, squarks, and gauginos in the context of generalized models of gauge-mediated supersymmetry, which reach as high as 2.3 TeV for strongly produced and 1.3 TeV for weakly produced supersymmetric partner pairs. KW - Gluino production KW - Supersymmetric models KW - Hypothetical particle physics models KW - Fortran code KW - Extension KW - Squark KW - Breaking KW - Decays KW - Model KW - Weak Y1 - 2018 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-226510 VL - 97 ER -